SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia ®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple ...

“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...